- Yale researchers publish study that a single dose of psilocybin counteracts symptoms of depression
- Administering drug to mice resulted in an approximately 10% increase in neuron size and density
- Cybin is focused on progressing psychedelic therapeutics
As news of psychedelic research continues to report breakthroughs — such as the recent news from a group of Yale researchers that a single dose of psilocybin counteracts symptoms of depression (https://ibn.fm/NCORl) — companies operating in the space, including Cybin (NEO: CYBN) (NYSE American: CYBN), are ideally positioned to see significant benefits and growth.
“Yale researchers found that a single dose of the naturally occurring psychedelic compound psilocybin can cause structural changes in the brain that counteract symptoms of depression,” reported a “Yale Daily News” article published this week. The article, titled “Yale Researchers Discover Healing Effects of Psychedelic Drug,” stated that, in a paper published in the “Neuron” journal, researchers at the Yale School of…
NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire is part of the InvestorBrandNetwork.